Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Phase 1
48
about 2.6 years
18–65
3 sites in AL, CA, TX
About this study
Researchers are testing the safety and tolerability of surovatamig in adults with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The trial will also look at how the medication affects the body's processes after it is given as a subcutaneous injection.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Surovatamig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), Safety of surovatamig: Incidence of AEs/SAEs leading to discontinuation of surovatamig, Tolerability of surovatamig: Incidence of treatment-related clinical laboratory abnormalities, Tolerability of surovatamig: Incidence of treatment-related vital signs abnormalities, Tolerability of surovatamig: Number of participants with abnormal ECG
Secondary: Serum Pharmacokinetics (PK) parameters of surovatamig - AUC0-last, Serum Pharmacokinetics (PK) parameters of surovatamig - AUCinf, Serum Pharmacokinetics (PK) parameters of surovatamig - AUCtau, Serum Pharmacokinetics (PK) parameters of surovatamig - Cmax
Immune